<DOC>
	<DOCNO>NCT01735617</DOCNO>
	<brief_summary>The purpose study gather safety effectiveness information new formulation Hydrocortisone ( Chronocort® ) use treat patient disease call congenital adrenal hyperplasia ( CAH ) . Hydrocortisone man-made version hormone cortisol , release body follow regular daily pattern . The objective study measure level hydrocortisone absorb bloodstream Chronocort® take affect hormone body . Since Chronocort® anticipate mimic release pattern cortisol body , hop patient CAH treat effectively manage disease .</brief_summary>
	<brief_title>Pilot Study Characterize Examine Pharmacokinetics Efficacy Chronocort® Adults With CAH</brief_title>
	<detailed_description>This study Phase 2 pilot study characterize examine pharmacokinetics efficacy profile Chronocort® adult congenital adrenal hyperplasia ( CAH ) . It design two-part , single cohort , open label , multiple dose Phase 2 pilot study : ( Part A ) characterize examine pharmacokinetics ( PK ) disease bio-marker behavior follow short-term dose Chronocort® ; ( Part B ) examine disease control six month dose titration Chronocort® adult CAH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>1 . Known CAH due 21hydroxylase deficiency ( classic CAH ) base hormonal genetic test currently treat hydrocortisone , prednisone , prednisolone dexamethasone stable dosage minimum 3 month . 2 . Male female patient age 18 . 3 . Provision sign write informed consent . 4 . Good general health . 5 . Females childbearing potential must negative pregnancy test initially visit . Females engage sexual intercourse must use medically acceptable method contraception ( define protocol , section 10.5 ) . 6 . Plasma renin activity must within clinically acceptable range screening ( less 1.5 time upper normal range ) . 1 . Comorbid condition require daily administration medication induces hepatic enzyme interfere metabolism glucocorticoid . 2 . Clinical biochemical evidence hepatic renal disease . Creatinine normal range elevate liver function test ( ALT AST ) &gt; 2 time upper limit normal . 3 . Females pregnant lactating . 4 . Women take estrogencontaining oral contraceptive pill take within 6 week recruitment . 5 . Patients take spironolactone . 6 . Patients inhaled oral steroid apart treatment CAH . 7 . Patients significant medical psychiatric condition opinion Investigator would preclude participation trial . 8 . Participation another clinical trial investigational license drug device within 3 month prior inclusion study . 9 . Patients history bilateral adrenalectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>congenital adrenal hyperplasia</keyword>
	<keyword>glucocorticoid</keyword>
	<keyword>cortisol</keyword>
	<keyword>adrenal</keyword>
</DOC>